CD17 is an intermediate glycosphingolipid from the metabolism of higher gangliosides that localizes to sphingolipid-sterol rafts. CD17 is detectable in monocytes, granulocytes, basophils, platelets, a subset of peripheral B cells (CD19+) and tonsil dendritic cells. It is rapidly down regulated on activated granulocytes and is upregulated on IL-2 activated T lymphocytes. CD17 binds to bacteria and may function in phagocytosis. VEGF-treated endothelial cells can produce CD17, which can then mediate signaling toward PECAM-1 expression and angiogenesis. Tumor necrosis factor Ī � (TNFĪ �)-induced astrogliosis (astrocyte proliferation and glial fibrillary acidic protein (GFAP) upregulation) in response to neuro-inflammation (i.e. spinal cord injury) causes an increase in intracellular levels of CD17. Aberrant levels of glycosphingolipids are a feature of cancer cells and may influence integrin clustering and intealization.
Host
Mouse
Immunogen
β-2 Microglobulin associated proteins from a detergent lysate of human PBL
Positive Control
Human PBL. Tonsil
Reactivity
Human
Recombinant
FALSE
Regulatory
RUO
Swissprot
Not Known
Uniprot
Not Known
Gene Id
Not Known
Buffer
200μg/ml of Ab purified from Bioreactor Concentrate. Prepared in 10mM PBS with 0.05% BSA; 0.05% azide. Also available WITHOUT BSA; azide at 1.0mg/ml.
Concentration
1.0mg/ml
Description
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Purity
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
Applications
FACS, IF
Description
Optimal dilution for a specific application should be determined., FACS ; IF
Dilution
FACS
0.5-1μg/million cells in 0.1ml
IF
0.5-1μg/ml
Reviews of Anti-CDw17 (Lactosylceramide or LacCer) Antibody BHA10207059